# Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori

> **NCT02873065** · PHASE4 · COMPLETED · sponsor: **Livzon Pharmaceutical Group Inc.**

## Conditions studied

- Helicobacter Pylori Eradication

## Interventions

- **DRUG:** Ilaprazole
- **DRUG:** Esoprazole

## Key facts

- **NCT ID:** NCT02873065
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** — (—)
- **Last updated:** 2016-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02873065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02873065, "Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02873065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*